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1. Introduction 
 
 Worldwide the incidence of melanoma is 
increasing and in spite of advances in local and systemic 
therapy, mortality continues to rise with 80% of skin 
cancer-related deaths attributable to melanoma. 
Similarly, in Hungary the incidence of melanoma has 
been progressively rising in the past decade. According 
the data of Hungarian National Cancer Registry and 
Center of Biostatistics in the last 10 years the number of 
melanoma cases has doubled in Hungary. 
 Tumour transplantation models present 
experimental evidence that tumours can be repressed by 
the immune system. These findings suggested the 
existence of tumour-associated antigens and formed the 
basis of “immune surveillance”. Although the idea of 
cancer immune surveillance resisted widespread 
acceptance until the 1990s, the better understanding of 
the mechanisms of immunoediting during tumour 
progression may provide new insights for improving 
cancer immunotherapy. 
 Immunotherapy is a general term referring to 
artificial activation of the immune system to induce 
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objective responses and/or disease stabilization. 
Immunotherapy enhances and encourages the patient's 
immune system to recognize and destroy cancer cells 
more effectively. Several types of immunotherapies are 
used in treating patients with melanoma. Some are being 
studied as adjuvant treatment. These drugs improve the 
ability of the body to find and destroy cancer cells. 
Immunotherapeutic interventions offer the hope for 
effective treatment against melanoma as it is considered 
traditionally as an immunogen tumour cancer because of 
its ability to undergo spontaneous regression. 
  
 Interferon 
 Interferons are pleiotropic molecules that share a 
number of biologic effects such as antiviral, 
antiproliferative and immunomodulatory actions. 
Interferons affect many organs and cause multiple side 
effects in most of the treated patients. In the long run, 
adjuvant interferon treatment has the most common and 
also clinically relevant psychological side effects. 
Fatigue, anhedonia, social isolation, psychomotor 
slowness is reported during treatment and is frequently 
accompanied by psychological side effects including 
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depression, irritability, anxiety, or suicide. These 
psychological problems may lead to a significant 
deterioration in the quality of life and often result in 
premature treatment discontinuation. Clinically 
significant depression developing during interferon 
therapy varies between 20% and 40% and is one of the 
most frequent reasons for premature therapy 
discontinuation. 10%–40% of patients additionally 
develop a full depressive disorder syndrome that can 
include suicidal ideation, aboulia, lack of motivation, 
social withdrawal, guilt, anhedonia, irritability, anxiety, 
and crying. 
 
 Ipilimumab - new therapies 
 The fast progress in understanding of 
immunobiology made significant break-through in 
immunotherapies that have radically changed and 
renewed the treatment of malignant melanoma. The 
approval of anti-cytotoxic T-lymphocyte anti-gen 4 
(CTLA-4) antibody ipilimumab by US FDA in 2011, as 
well as the new drugs including antibodies to 
programmed cell death 1 (PD-1) have extended the 
potential of immunotherapy for advanced melanoma. 
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 Ipilimumab was the first immunotherapy that 
showed a benefit for overall survival in two controlled 
trials in metastatic melanoma. 
 During ipilimumab therapy, most often 
autoimmune side effects were reported (colitis, 
thyreoiditis, hepatitis). Depression, confusion, insomnia, 
mental status changes are named as expected adverse 
events in ipilimumab treatment, but there are only few 
data in the literature.  
2. Aims 
 
The chief aim of the research was to measure and 
identify psychiatric adverse events, such as changes in 
depressed mood and anxiety using psychological self-
rating scales during immunotherapies used in the 
treatment of malignant melanoma. It was important to 
identify the factors which could influence the possible 
psychological (side-)effects of these therapies. 
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Interferon-induced depression - first study 
 
In the first study the primary aim was to 
investigate the psychological side effects of low-dose 
interferon treatment in melanoma patients. Specifically, 
we tested the protective effect of social support on 
psychological side effects. We hypothesised that 
 the level of depression significantly increases 
during long-term interferon treatment 
 the level of anxiety significantly increases during 
long-term interferon treatment 
 different socioeconomic aspects (sex, age, family 
status, education, financial status) have an effect 
on emerging depression or anxiety during long-
term interferon therapy 
 greater social support will be associated with 
better adjustment (namely less depressive and 
anxiety symptoms during treatment) 
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Ipilimumab vs. interferon - second study 
 
The primary aim of this study was to measure 
psychiatric adverse events, such as changes in depressed 
mood during ipilimumab treatment and compare the 
results to the psychiatric side effect profile of long-term 
low-dose interferon treatment. We hypothesised that 
 both immuntherapies are associated with long-
term psychiatric side effects including depression 
and anxiety 
 the ipilimumab-treated group has increased 
baseline level of depression and anxiety 
 significant increase in the level of depression and 
anxiety will occur during ipilimumab treatment 
 significant increase in the level of depression and 
anxiety will be observable during long-term 
interferon treatment 
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3. Methods 
 
In this thesis two study paradigms were described. 
 
Recruitment and design 
 
Patients were recruited at the Department of 
Oncodermatology in the National Institute of Oncology 
(Budapest, Hungary) for the two open-label follow-up 
studies. All subjects completed a psychological 
questionnaire booklet. 
 
Background questionnaire 
 
Demographic data, including sex, age, home, 
family and financial status, and level of education were 
assessed by a standardised background questionnaire in 
both study.  
3.1. Interferon-induced depression – first study 
 
3.1.1. Participants 
 
127 patients were recruited for this open-label 
follow-up study. All patients received interferon alpha 2a 
treatment in a weekly dose of 3X3 MIU/week 
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subcutaneously and regularly attended control 
examinations at month 0, 1, 3, 6, 9, 12. 
 
3.1.2. Questionnaires 
 
The Beck Depression Inventory was used to 
detect symptoms of depression.  
The State-Trait Anxiety Inventory (STAI) was 
used to measure anxiety symptoms. 
Social support was measured with the Social 
Dimension Scale developed by Caldwell et al. 
3.1.3. Other measures 
 
The data of thickness and invasion of primary 
tumour (Breslow's depth and Clark invasion) were 
determined by histopathological examinations. 
 
3.1.4. Statistics 
 
Data were analysed by SPSS 21 for Windows 
(IBM). Repeated measures ANCOVA was used to 
analyse the effect of interferon treatment during the 
follow-up on psychometric measures. In all calculations 
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ANCOVAs Greenhouse-Geisser correction was applied 
and age, sex, financial status, social support, education 
were co-variants. The level of significance was p=0.05, 
two-tailed.  
3.2. Ipilimumab vs. interferon – second study 
 
3.2.1. Participants 
 
Two groups were recruited for this study: 
IPI-Group: included 10 participants treated with 
ipilimumab. Patients received 3 mg/kg YERVOY® four 
times in every 3rd week. Patients were controlled at week 
0, 3, 6, 9. 
The interferon group (INF-α-Group) included 18 
participants (independent from the previous study). 
Patients received interferon-alpha 2a treatment in a 
weekly dose of 3X3 MIU/week subcutaneously and they 
were checked at month 0, 1, 3, 6.  
3.2.2. Questionnaires 
 
To detect symptoms of depression, we used the 
Zung Self-Rating Depression Scale (SDS). 
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The level of anxiety was measured with the State-
Trait Anxiety Inventory (STAI). 
Social support was measured with an adapted 
version of the Social Dimension Scale developed by 
Caldwell et al. 
3.2.3. Statistics 
 
Data were analysed by SPSS 21 for Windows. 
Between-group comparisons were evaluated by t-tests 
and by chi-square tests. Repeated measures ANCOVA 
was used to analyse the time-effect of drugs on 
psychometric measures in the longitudinal data. In all 
calculations ANCOVAs Greenhouse-Geisser correction 
was applied and age, sex, and social support were co-
variants. The level of significance was p=0.05, two-
tailed. 
11 
 
4. Results 
 
4.1. Interferon-induced depression - first study 
 
4.1.1. Baseline results 
At baseline none of the patients had depression or 
anxiety scores above the Hungarian cut-off score for 
clinical depression or anxiety. Higher educated patients, 
patients with better financial conditions and male patients 
scored lower on BDI compared to the other group. There 
were no significant differences in BDI depression scores 
at baseline according to social support, family status or 
tumour parameters. 
At baseline women and subjects with very bad or 
bad financial situations scored higher on the STAI-State 
anxiety subscale compared to the other groups. There 
were no significant differences according to the other 
investigated factors. 
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4.1.2. Longitudinal effect of interferon 
treatment on depression 
 
In the study group, BDI depression scores steadily 
and significantly increased during the treatment. Among 
the investigated co-variants only social support showed a 
significant effect on the increase of BDI depression 
scores. According to post-hoc pair-wise comparisons, 
social support effect became significant at month 9 and 
with increasing effect at month 12. 
4.1.3. Effect of high versus low social support 
on depressogenic side effects of interferon treatment 
 
To further investigate how social support 
modulates the depressogenic side effect of interferon 
treatment two social support groups were classified 
according to the mean value of Social Dimension Scale 
scores: patients in Group 1 (N=65) had scores above 15, 
so this was the better-supported group, and in Group 2 
(N=62) subjects scored 15 or below 15, so this group 
contained the lower-supported patients. The BDI 
depression score difference steadily increased between 
the two groups from the visit at month 6. The better-
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supported group scored lower from this point compared 
to the other group and the difference reached significance 
at month 9 . 
4.1.4. Longitudinal effect of interferon 
treatment on anxiety 
 
There were no significant changes in STAI state 
anxiety scores during interferon treatment in spite of a 
temporary increase at the first control visit (month 1). 
Sex had a significant main effect on interferon 
treatment-induced anxiety symptoms. Post hoc analysis 
demonstrated that female patients had increased anxiety 
scores from month 6 compared to males. No other co-
variants in the model had a significant effect on STAI 
state anxiety scores during the treatment. 
4.2. Ipilimumab vs. interferon – second study 
 
4.2.1. Baseline results 
No significant differences were measurable in 
demographic factors between the two groups. At 
baseline, IPI-Group (ipilimumab) had higher level of 
depression scores compared to INF-α-Group (interferon-
alpha 2a; t=2.176, df=26, p<0.039). 
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Regarding anxiety, no significant differences were found 
at baseline (t=-0.044, df=26, p=0.965) comparing the two 
study groups. 
4.2.2. Drug effect in time on depression 
 
In IPI-Group there were no significant changes in 
depression scores using repeated measures ANCOVA. In 
INF-α-Group depression scores steadily and significantly 
increased during treatment. 
4.2.3. Drug effect in time on anxiety 
 
No significant drug effect in time was 
demonstrated in the IPI-Group on anxiety scores. There 
were no significant changes in anxiety scores in the INF-
α-Group. In both groups anxiety scores increased for the 
2nd time point. 
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5. Conclusions 
 
The above studies further supported that 
immunotherapy of melanoma patients increases the risk 
of psychological distress. We demonstrated that anxiety 
and depression are differentially influenced by interferon 
alpha treatment. Only depression but not anxiety 
increased significantly during the 12-month follow-up. In 
addition, the depressogenic side effect of interferon alpha 
treatment can be diminished by increased social support. 
Finally, we demonstrated that ipilimumab has fewer 
psychological side effects than interferon alpha, probably 
because of the different biological pathways they act 
through. 
The main findings and conclusions of the studies: 
 the studies provided evidence for the protective 
effect of social support in the development of 
low-dose interferon alpha treatment-induced 
depression in melanoma patients 
 the results suggest that environmental effects such 
as social support are able to moderate the 
depressogenic effect of activation in the pro-
16 
 
inflammatory cytokine pathway, possibly by 
acting through overlapping biological processes 
 significant effect of interferon alpha treatment on 
anxiety could not be demonstrated 
 female patients had significantly more anxiety 
symptoms from the 6th month of the therapy 
compared to male patients 
 thus depressive symptoms and anxiety symptoms 
are not equally influenced by the pro-
inflammatory cytokine pathway 
 no significant drug effect was demonstrated in 
ipilimumab-treated patients on anxiety scores 
 no significant drug effect was demonstrated in 
ipilimumab-treated patients on depression scores 
 ipilimumab elicited fewer psychological side-
effects compared to interferon-alpha 
immunotherapy which suggests a better 
psychological side effects profile for ipilimumab 
treatment that could be especially important in 
advanced stage melanoma and in patients at risk 
for depression and anxiety 
 our studies further support the importance of 
taking positive and negative environmental 
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factors into consideration to be able to identify 
risk biomarkers or genes for depression. 
In conclusion, although both IFN-alpha and 
immune checkpoint inhibitors increase tumour-specific 
immune response, their psychological side-effect profiles 
are strikingly different. Thus our results emphasize that 
considering psychiatric and psychological history beside 
oncological indications during treatment choice may 
advance personalised treatment in melanoma patients. 
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